Business Context and Reporting Period
This Form 8-K was filed by Croff Enterprises, Inc. on June 17, 2008. The filing reports a change in control of the registrant. The company is identified as a shell company both prior to and following the reported transaction. Note: The request metadata references "Therapeuticsmd, Inc.", but the source text explicitly identifies the registrant as Croff Enterprises, Inc.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The document states that the financial information provided in the Company's Form 10-K for the fiscal year ended December 31, 2007, and Form 10-Q for the quarter ended March 31, 2008, remains accurate.
Transaction Specifics:
- Acquisition Cost: $163,579.40 in cash.
- Shares Acquired: 146,000 shares of common stock.
- Ownership Stake: Approximately 28.3% of issued and outstanding shares (excluding treasury shares).
- Funding Source: Personal funds of Terrace Lane, LLC.
Material Changes
The primary material change is the transfer of control from the Jensen family and associated entities to Terrace Lane, LLC. This transaction resulted in a complete turnover of the Board of Directors and executive leadership.
- Departures: Gerald L. Jensen (Chairman/CEO), Julian Jensen (Director), Richard Mandel (Director), and Alex Forest (Secretary) resigned.
- Appointments: Gregory R. Woodhill, Michael Chester, and David S. Hamilton were appointed to the Board of Directors.
- Executive Changes: Gregory R. Woodhill was appointed President, Chief Financial Officer, and Secretary effective June 18, 2008.
Outlook, Risks, and Management Commentary
Management Commentary: The new management team consists of individuals with backgrounds in restaurant equipment sales, music promotion, and securities law. No material compensatory plans or contracts have been established for the new officers or directors at this time.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ from anticipated results due to risks and uncertainties. The company states it is unaware of any arrangements that may result in a further change of control.
Investor Verification Checklist
- Verify the discrepancy between the request metadata ("Therapeuticsmd, Inc.") and the filing registrant ("Croff Enterprises, Inc.").
- Confirm the current status of the 146,000 shares purchased by Terrace Lane, LLC and the resulting 28.3% ownership stake.
- Review the Form 10-K (ended Dec 31, 2007) and Form 10-Q (ended Mar 31, 2008) for the most recent financial data, as this 8-K contains no new financial statements.
- Monitor for future filings regarding the appointment of board committees and the establishment of compensation plans for the new leadership.
- Assess the strategic intent of the new management team, given the company's status as a shell company.